IMEMR
EMRO
66.92
Index Copernicus
ICICICICICICICIC
Volume 6, Issue 2 (2025)
J Clinic Care Skill 2025, 6(2): 89-103 |
Back to browse issues page
Article Type:
Subject:
Ethics code: IR.YUMS.REC.1400.119
History
Received: 2025/05/15 | Accepted: 2025/06/28 | Published: 2025/07/1
Received: 2025/05/15 | Accepted: 2025/06/28 | Published: 2025/07/1
How to cite this article
Fazeli M, Malekzadeh M, Bayatmanesh H, Neysarian P, Arefkhah N, Sedaghattalab M. Effects of Interferon Beta-1 and Dexamethasone on the Treatment of Hospitalized COVID-19 Patients. J Clinic Care Skill 2025; 6 (2) :89-103
URL: http://jccs.yums.ac.ir/article-1-403-en.html
URL: http://jccs.yums.ac.ir/article-1-403-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Authors
M.A. Fazeli1, M. Malekzadeh2, H. Bayatmanesh3, P. Neysarian4, N. Arefkhah1, M. Sedaghattalab *5
1- Department of Infectious Disease, Faculty of Medicine, Yasuj University of Medical Sciences, Yasuj, Iran
2- Social Determinant of Health Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
3- “Imam Sajad Hospital” and “Department of Nursing, Faculty of Nursing & Midwifery”, Yasuj University of Medical Sciences, Yasuj, Iran
4- “Shahid Jalil Hospital” and “Department of Midwifery, Faculty of Nursing & Midwifery”, Yasuj University of Medical Sciences, Yasuj, Iran
5- Department of Internal Medicine, Faculty of Medicine, Yasuj University of Medical Sciences, Yasuj, Iran
2- Social Determinant of Health Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
3- “Imam Sajad Hospital” and “Department of Nursing, Faculty of Nursing & Midwifery”, Yasuj University of Medical Sciences, Yasuj, Iran
4- “Shahid Jalil Hospital” and “Department of Midwifery, Faculty of Nursing & Midwifery”, Yasuj University of Medical Sciences, Yasuj, Iran
5- Department of Internal Medicine, Faculty of Medicine, Yasuj University of Medical Sciences, Yasuj, Iran
Abstract (315 Views)
Aims: Despite the urgent need to treat the COVID-19 pandemic, no effective treatment has been identified to date. The present study aimed to compare the effects of interferon Beta-1 and dexamethasone on the treatment of hospitalized COVID-19 patients.
Materials & Methods: This phase 2, open-label, randomized trial examined adult patients who were admitted to hospitals in Yasuj, Iran, from October 2021 to May 2022 due to COVID-19. Patients were randomly assigned to intervention group 1 (88 patients), which included remdesivir, interferon beta-1, and dexamethasone, and intervention group 2 (88 patients), which included remdesivir and dexamethasone, in a ratio of 1:1. The mean arterial blood O2 saturation and length of hospitalization for both groups were compared.
Findings: The two groups did not show a significant difference in terms of demographic characteristics and disease-related parameters at baseline (p>0.05). The mean O2 saturation at the time of discharge for group 1 (90.14±10.72) and group 2 (92.54±3.19) demonstrated a significant difference (p<0.05). The mean length of hospitalization for group 1 (7.02±2.56) and group 2 (5.73±2.04) was significantly different (p<0.01). There was a significant difference between the number of deaths in group 1 (7 patients) and group 2 (0 patients; p<0.01).
Conclusion: The administration of remdesivir and dexamethasone, compared to remdesivir, dexamethasone, and interferon, results in a decreased length of hospitalization, reduced mortality, and improved O2 saturation.
Materials & Methods: This phase 2, open-label, randomized trial examined adult patients who were admitted to hospitals in Yasuj, Iran, from October 2021 to May 2022 due to COVID-19. Patients were randomly assigned to intervention group 1 (88 patients), which included remdesivir, interferon beta-1, and dexamethasone, and intervention group 2 (88 patients), which included remdesivir and dexamethasone, in a ratio of 1:1. The mean arterial blood O2 saturation and length of hospitalization for both groups were compared.
Findings: The two groups did not show a significant difference in terms of demographic characteristics and disease-related parameters at baseline (p>0.05). The mean O2 saturation at the time of discharge for group 1 (90.14±10.72) and group 2 (92.54±3.19) demonstrated a significant difference (p<0.05). The mean length of hospitalization for group 1 (7.02±2.56) and group 2 (5.73±2.04) was significantly different (p<0.01). There was a significant difference between the number of deaths in group 1 (7 patients) and group 2 (0 patients; p<0.01).
Conclusion: The administration of remdesivir and dexamethasone, compared to remdesivir, dexamethasone, and interferon, results in a decreased length of hospitalization, reduced mortality, and improved O2 saturation.
Keywords:
References
1. Tsang HF, Chan LWC, Cho WCS, Yu ACS, Yim AKY, Chan AKC, et al. An update on COVID-19 pandemic: The epidemiology, pathogenesis, prevention and treatment strategies. Expert Rev Anti Infect Ther. 2021;19(7):877-88. [Link] [DOI:10.1080/14787210.2021.1863146]
2. Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221-36. [Link] [DOI:10.1080/22221751.2020.1719902]
3. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730-41. [Link] [DOI:10.1111/all.14238]
4. Spinato G, Fabbris C, Polesel J, Cazzador D, Borsetto D, Hopkins C, et al. Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection. JAMA. 2020;323(20):2089-90. [Link] [DOI:10.1001/jama.2020.6771]
5. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693-704. [Link] [DOI:10.1056/NEJMoa2021436]
6. Abdelrahman Z, Liu Q, Jiang S, Li M, Sun Q, Zhang Y, et al. Evaluation of the current therapeutic approaches for COVID-19: A systematic review and a meta-analysis. Front Pharmacol. 2021;12:607408. [Link] [DOI:10.3389/fphar.2021.607408]
7. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The CoDEX randomized clinical trial. JAMA. 2020;324(13):1307-16. [Link] [DOI:10.1001/jama.2020.17021]
8. Singh AK, Majumdar S, Singh R, Misra A. Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective. Diabetes Metab Syndr. 2020;14(5):971-8. [Link] [DOI:10.1016/j.dsx.2020.06.054]
9. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax. 2004;59(3):252-6. [Link] [DOI:10.1136/thorax.2003.012658]
10. Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol. 2003;52(Pt 8):715-20. [Link] [DOI:10.1099/jmm.0.05320-0]
11. Scagnolari C, Vicenzi E, Bellomi F, Stillitano MG, Pinna D, Poli G, et al. Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther. 2004;9(6):1003-11. [Link] [DOI:10.1177/135965350400900618]
12. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. [Link] [DOI:10.1038/s41467-019-13940-6]
13. Kalil AC, Mehta AK, Patterson TF, Erdmann N, Gomez CA, Jain MK, et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: A double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(12):1365-76. [Link] [DOI:10.1016/S2213-2600(21)00384-2]
14. Ader F, Peiffer-Smadja N, Poissy J, Bouscambert-Duchamp M, Belhadi D, Diallo A, et al. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect. 2021;27(12):1826-37. [Link] [DOI:10.1016/j.cmi.2021.05.020]
15. Khamis F, Al Naabi H, Al Lawati A, Ambusaidi Z, Al Sharji M, Al Barwani U, et al. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. Int J Infect Dis. 2021;102:538-43. [Link] [DOI:10.1016/j.ijid.2020.11.008]
16. Lee YH, Hong CM, Kim DH, Lee TH, Lee J. Clinical course of asymptomatic and mildly symptomatic patients with coronavirus disease admitted to community treatment centers, South Korea. Emerg Infect Dis. 2020;26(10):2346-52. [Link] [DOI:10.3201/eid2610.201620]
17. Noreen S, Maqbool I, Madni A. Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic. Eur J Pharmacol. 2021;894:173854. [Link] [DOI:10.1016/j.ejphar.2021.173854]
18. Sinha S, Rosin NL, Arora R, Labit E, Jaffer A, Cao L, et al. Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19. Nat Med. 2022;28(1):201-11. [Link] [DOI:10.1038/s41591-021-01576-3]
19. Arabi YM, Shalhoub S, Mandourah Y, Al-Hameed F, Al-Omari A, Al Qasim E, et al. Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: A multicenter observational study. Clin Infect Dis. 2020;70(9):1837-44. [Link] [DOI:10.1093/cid/ciz544]
20. Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob Agents Chemother. 2020;64(9):e01061-20. [Link] [DOI:10.1128/AAC.01061-20]
21. Alavi Darazam I, Shokouhi S, Pourhoseingholi MA, Naghibi Irvani SS, Mokhtari M, Shabani M, et al. Role of interferon therapy in severe COVID-19: The COVIFERON randomized controlled trial. Sci Rep. 2021;11(1):8059. [Link] [DOI:10.1038/s41598-021-86859-y]
22. Durbin JE, Fernandez-Sesma A, Lee CK, Rao TD, Frey AB, Moran TM, et al. Type I IFN modulates innate and specific antiviral immunity. J Immunol. 2000;164(8):4220-8. [Link] [DOI:10.4049/jimmunol.164.8.4220]
23. Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020;178:104791. [Link] [DOI:10.1016/j.antiviral.2020.104791]
24. Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(2):196-206. [Link] [DOI:10.1016/S2213-2600(20)30511-7]
25. Su S, Jiang S. A suspicious role of interferon in the pathogenesis of SARS-CoV-2 by enhancing expression of ACE2. Signal Transduct Target Ther. 2020;5(1):71. [Link] [DOI:10.1038/s41392-020-0185-z]
26. Salto-Alejandre S, Palacios-Baena ZR, Arribas JR, Berenguer J, Carratalà J, Jarrín I, et al. Impact of early interferon-β treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort. Biomed Pharmacother. 2022;146:112572. [Link] [DOI:10.1016/j.biopha.2021.112572]
27. WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed antiviral drugs for Covid-19-interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497-511. [Link] [DOI:10.1056/NEJMoa2023184]